Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stake Boosted by Nordea Investment Management AB

Nordea Investment Management AB boosted its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 4.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 194,883 shares of the company’s stock after purchasing an additional 8,257 shares during the quarter. Nordea Investment Management AB’s holdings in Kiniksa Pharmaceuticals were worth $3,818,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Braidwell LP increased its position in shares of Kiniksa Pharmaceuticals by 40.6% in the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after acquiring an additional 836,210 shares in the last quarter. FMR LLC grew its position in Kiniksa Pharmaceuticals by 36,925.0% during the 3rd quarter. FMR LLC now owns 696,810 shares of the company’s stock worth $17,413,000 after purchasing an additional 694,928 shares in the last quarter. Millennium Management LLC grew its position in Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares in the last quarter. Jane Street Group LLC raised its stake in Kiniksa Pharmaceuticals by 1,064.4% during the 3rd quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock valued at $8,624,000 after purchasing an additional 315,456 shares during the period. Finally, Rubric Capital Management LP lifted its holdings in shares of Kiniksa Pharmaceuticals by 10.2% in the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock valued at $45,165,000 after purchasing an additional 223,094 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on KNSA shares. Evercore ISI upped their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. upped their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $36.60.

Insider Buying and Selling

In related news, COO Eben Tessari sold 17,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the sale, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This represents a 13.39 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at $492,449.10. This trade represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,092 shares of company stock worth $673,039. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock opened at $19.93 on Friday. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -142.35 and a beta of 0.29. The stock has a 50-day simple moving average of $21.13 and a 200-day simple moving average of $23.21. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same quarter last year, the firm earned ($0.20) earnings per share. Kiniksa Pharmaceuticals’s revenue was up 67.4% compared to the same quarter last year. As a group, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.